These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 33793589

  • 1. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
    Yoo R, So H, Seo E, Kim M, Lee J.
    PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
    [Abstract] [Full Text] [Related]

  • 2. Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
    Yoo RN, Kim SH, Lee J.
    J Korean Med Sci; 2017 Jan; 32(1):22-28. PubMed ID: 27914127
    [Abstract] [Full Text] [Related]

  • 3. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients.
    Makmor-Bakry M, Ahmat A, Shamsuddin A, Lau CL, Ramli R.
    Anaesthesiol Intensive Ther; 2019 Jan; 51(3):218-223. PubMed ID: 31434472
    [Abstract] [Full Text] [Related]

  • 4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA.
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [Abstract] [Full Text] [Related]

  • 5. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R, Davis SL, Levine DP, Rybak MJ.
    Clin Infect Dis; 2011 Apr 15; 52(8):975-81. PubMed ID: 21460309
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Aug 15; 58(8):4636-41. PubMed ID: 24890596
    [Abstract] [Full Text] [Related]

  • 7. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
    Prybylski JP.
    Pharmacotherapy; 2015 Oct 15; 35(10):889-98. PubMed ID: 26497475
    [Abstract] [Full Text] [Related]

  • 8. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
    Hsu AJ, Hamdy RF, Huang Y, Olson JA, Ghobrial S, Gerber JS, Hersh AL, Tamma PD.
    J Pediatric Infect Dis Soc; 2018 Dec 03; 7(4):338-341. PubMed ID: 28992126
    [Abstract] [Full Text] [Related]

  • 9. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.
    Int J Antimicrob Agents; 2014 Feb 03; 43(2):179-83. PubMed ID: 24315788
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Covvey JR, Erickson O, Fiumara D, Mazzei K, Moszczenski Z, Slipak K, Nemecek BD, Zimmerman DE, Guarascio AJ.
    Ann Pharmacother; 2020 Jul 03; 54(7):644-651. PubMed ID: 31888350
    [Abstract] [Full Text] [Related]

  • 11. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD.
    Int J Antimicrob Agents; 2015 Dec 03; 46(6):689-95. PubMed ID: 26555059
    [Abstract] [Full Text] [Related]

  • 12. Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in pediatric patients with Staphylococcus aureus bacteremia.
    Ruiz J, García-Robles A, Marqués MR, Company MJ, Solana A, Poveda JL.
    Minerva Pediatr (Torino); 2022 Oct 03; 74(5):525-529. PubMed ID: 29651827
    [Abstract] [Full Text] [Related]

  • 13. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Oct 03; 60(10):5841-8. PubMed ID: 27431221
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.
    Hahn A, Frenck RW, Allen-Staat M, Zou Y, Vinks AA.
    Ther Drug Monit; 2015 Oct 03; 37(5):619-25. PubMed ID: 26378371
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A, Swamy S, Jacob K, Sharma R, Kohlhoff SA, Hammerschlag MR.
    Minerva Pediatr; 2018 Jun 03; 70(3):207-211. PubMed ID: 28006894
    [Abstract] [Full Text] [Related]

  • 16. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H.
    J Clin Pharm Ther; 2016 Aug 03; 41(4):399-402. PubMed ID: 27144370
    [Abstract] [Full Text] [Related]

  • 17. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
    Beccari MV, Seabury RW, Mogle BT, Kufel WD, Miller CD, Steele JM.
    J Am Pharm Assoc (2003); 2020 Aug 03; 60(5):729-733. PubMed ID: 32224054
    [Abstract] [Full Text] [Related]

  • 18. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
    Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, Tsuchida T, Uchino M, Ikeuchi H.
    J Infect Chemother; 2011 Feb 03; 17(1):52-7. PubMed ID: 20625789
    [Abstract] [Full Text] [Related]

  • 19. Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?
    Johnston MM, Huang V, Hall ST, Buckley MS, Bikin D, Barletta JF.
    Diagn Microbiol Infect Dis; 2021 Oct 03; 101(2):115442. PubMed ID: 34192639
    [Abstract] [Full Text] [Related]

  • 20. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP, Lin JC, Chiu SK, Yeh YC, Lin TY, Yang YS, Wang YC, Wang NC, Yeh KM, Chang FY.
    J Microbiol Immunol Infect; 2014 Feb 03; 47(1):15-22. PubMed ID: 23040238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.